Exicure Completes the Last Patient, Last Visit in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant

Stock Information for Augmedix Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Augmedix Inc.

Exicure, Inc. Reports Third Quarter 2025 Financial Results
New Burixafor Clinical Data to be Presented as an Oral Presentation at the 2025 ASH Annual Meeting
Halper Sadeh LLC Encourages Exicure, Inc. Shareholders to Contact the Firm to Discuss Their Rights
Exicure Highlights Recent Achievements and Near-term Strategic Priorities
Exicure, Inc. Reports Second Quarter 2025 Financial Results
Exicure, Inc. (Nasdaq: XCUR) Regains Compliance with Nasdaq Filing Requirements
Exicure, Inc. Reports First Quarter 2025 Financial Results
Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.